logo

Mallinckrodt Plc (MNK)



Trade MNK now with
  Date
  Headline
8/15/2019 6:46:29 AM Mallinckrodt Reports Positive Top-Line Results From Pivotal Phase 3 CONFIRM Trial Of Terlipressin
8/12/2019 6:58:27 AM Mallinckrodt Confirms Enrollment Of First Patient In Phase 2a Study Of MNK-6106 In Hepatic Cirrhosis And Chronic HE
8/6/2019 6:10:50 AM Mallinckrodt Q2 Adj. EPS $2.53 Vs. $2.16 Prior Year
7/18/2019 6:56:57 AM Mallinckrodt, Silence Therapeutics Collaborate To Develop, Commercialize RNAi Therapeutics
7/18/2019 6:55:57 AM Mallinckrodt Agrees To Make An Equity Investment Of $5 Mln In Silence Therapeutics
6/24/2019 6:56:38 AM Mallinckrodt Achieves 50% Enrollment For Phase 2B Trial Investigating The Use Of Acthar Gel In ALS
6/13/2019 6:49:34 AM Mallinckrodt Says Phase 4 Multicenter Study Assessing Efficacy And Safety Of Acthar® Gel Meets Primary Measures
5/29/2019 7:03:50 AM Mallinckrodt Says Positive Open-Label Results From Phase 4 Acthar® Gel Clinical Trial In RA To Be Presented At EULAR
5/28/2019 6:49:48 AM Mallinckrodt Announces Updated Plans For Spin-off Of New Company Consisting Of Specialty Generics Business
5/21/2019 4:43:45 PM Mallinckrodt Elects Carlos Paya To Its Board Of Directors
5/21/2019 7:55:48 AM Mallinckrodt Files Suit In Federal District Court Against HHS And CMS To Protect Medicaid Patient Access To Acthar Gel
5/14/2019 6:56:33 AM Mallinckrodt Completes Enrollment Of Phase 3 Terlipressin CONFIRM Trial
5/7/2019 6:43:17 AM Mallinckrodt Q1 EPS From Cont. Opns $1.83; Adjusted EPS $1.94
5/7/2019 6:42:36 AM CPP And Mallinckrodt Announce Results From Pivotal Phase 3 Trial Of CPP-1X/Sulindac